Sanjay Chandrasekaran, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Hematology and Oncology Division. He specializes in hematology and oncology, with a focus on melanoma, advanced skin cancer, and soft tissue and bone sarcomas.
Dr. Chandrasekaran earned his medical degree at the University of Washington School of Medicine. He completed joint residency and advanced fellowship training in internal medicine, hematology, and medical oncology through the physician-scientist pathway at Emory University and its Winship Cancer Institute.
Certified by the American Board of Internal Medicine, Dr. Chandrasekaran joined the UT Southwestern faculty in 2021.
He is a member of several professional associations, including the American Society of Clinical Oncology (ASCO) and the American Medical Association.
He has published numerous academic articles, delivered multiple presentations, and served as a grant reviewer for the When Everyone Survives Leukemia Research Foundation.
During fellowship training, Dr. Chandrasekaran received a Conquer Cancer Foundation of ASCO Merit Award and was the recipient of the 2020 Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group’s Paul Carbone, MD Fellowship Award.
- Medical School
- University of Washington (2014)
- Emory University School of Medicine (2016), Internal Medicine
- Emory University School of Medicine - Emory Winship Cancer Institute (2021), Hematology Oncology
- 20/20 in 2020: seeking clarity on the management of stage III melanoma in a rapidly changing treatment environment.
- Chandrasekaran S, Lawson DH, Ann Transl Med 2020 Jun 8 12 776
- Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression.
- Chandrasekaran S, Sasaki M, Scharer CD, Kissick HT, Patterson DG, Magliocca KR, Seykora JT, Sapkota B, Gutman DA, Cooper LA, Lesinski GB, Waller EK, Thomas SN, Kotenko SV, Boss JM, Moreno CS, Swerlick RA, Pollack BP, Mol Cancer Res 2019 12 17 12 2395-2409
- Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study.
- Ju M, Kao GD, Steinmetz D, Chandrasekaran S, Keefe SM, Guzzo TJ, Christodouleas JP, Hahn SM, Dorsey JF, Cancer Biol Ther 2014 Jun 15 6 683-7
- Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.
- Macarthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta M, Chapman C, Lustig RA, Wileyto EP, Hahn SM, Dorsey JF, Cancer Res 2014 Apr 74 8 2152-9
- 18F-fluorothymidine-pet imaging of glioblastoma multiforme: effects of radiation therapy on radiotracer uptake and molecular biomarker patterns.
- Chandrasekaran S, Hollander A, Xu X, Benci JL, Davis JJ, Dorsey JF, Kao G, ScientificWorldJournal 2013 2013 796029
- An integrated method for reproducible and accurate image-guided stereotactic cranial irradiation of brain tumors using the small animal radiation research platform.
- Baumann BC, Benci JL, Santoiemma PP, Chandrasekaran S, Hollander AB, Kao GD, Dorsey JF, Transl Oncol 2012 Aug 5 4 230-7
- Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.
- Cengel KA, Voong KR, Chandrasekaran S, Maggiorella L, Brunner TB, Stanbridge E, Kao GD, McKenna WG, Bernhard EJ, Neoplasia 2007 Apr 9 4 341-8
Honors & Awards
- Paul Carbone, MD Fellowship Award
ECOG-ACRIN Cancer Research Group (2020)
- Merit Award
Conquer Cancer Foundation of the American Society of Clinical Oncology (2019)
- Elkin Fellowship Award
Winship Cancer Institute of Emory University (2017-2018)
- Postdoctoral Fellow
National Institutes of Health / National Research Service Award (NIH / NRSA) (2017-2020)
- American Medical Association
- American Society of Clinical Oncology